Will ALGS' earnings momentum continue in 2025?

**Aligos Therapeutics (ALGS) is unlikely to experience a turnaround in earnings momentum in 2025**, based on the following points:

1. **Current Financial Performance and Analyst Expectations**: Aligos Therapeutics reported a significant decline in revenue and earnings. The estimated EPS for Q1 2025 is -$2.8, and the estimated revenue is $1 million. This indicates a continued struggle for the company in terms of profitability.

2. **Recent Performance Trends**: The company's stock price has experienced a significant decrease of 15.13%. Additionally, the company's earnings per share (EPS) for the previous quarter was -$0.22, which was below the consensus estimate. This recent underperformance suggests that the company's earnings momentum is not expected to pick up soon.
3. **Cash Flow and Financial Position**: Aligos Therapeutics has seen a decrease in cash and cash equivalents, with the total amount decreasing from $135.7 million to $112.7 million. This reduction in cash reserves could limit the company's ability to fund operations and invest in growth, which are necessary for a potential earnings recovery.
4. **Institutional Confidence**: There has been a decrease in institutional confidence, as evidenced by Baker BROS. Advisors LP decreasing its stake in the company by 96%. This could reflect a broader market skepticism about the company's future prospects.
5. **Market Sentiment and Analyst Ratings**: The consensus for Aligos Therapeutics' future earnings is negative, with analysts expecting EPS of -$1 for the current fiscal year and the next fiscal year. This sentiment is further reinforced by the "Buy" rating from HC Wainwright with a target price of $75.00, which is significantly higher than the current price. However, the high target price does not necessarily indicate an expectation of earnings growth but rather a potential for future value if the drug candidate succeeds.
6. **Lack of Positive Earnings Predictions**: There are no positive earnings predictions for Aligos Therapeutics in the near future. The only prediction for Q3 2024 expects earnings of -$4.40 per share, which is below the current consensus estimate for that quarter.

In conclusion, the available data and market sentiment suggest that Aligos Therapeutics is not on a path to recover its earnings momentum in 2025. The company's financial performance is expected to remain under pressure due to a combination of revenue declines, negative earnings projections, and a lack of institutional confidence.